Prothena Corporation plc (PRTA) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Company: Prothena Corporation plc
Reporting Period: Quarter ended September 30, 2024
Business Overview: Prothena is a late-stage clinical biotechnology company focused on protein dysregulation, targeting neurodegenerative and rare peripheral amyloid diseases. Key programs include birtamimab (AL amyloidosis), PRX012 and PRX123 (Alzheimer's disease), and partnered programs with Roche (prasinezumab for Parkinson's), Bristol Myers Squibb (BMS), and Novo Nordisk.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $970 | $84,866 | $133,034 | $91,054 |
| Net Loss | $(59,001) | $21,907 (Income) | $(64,354) | $(79,552) |
| Diluted EPS | $(1.10) | $0.38 | $(1.20) | $(1.50) |
| Operating Expenses | $67,483 | $74,558 | $222,698 | $203,575 |
| Cash & Equivalents (End of Period) | $519,262 (as of Sept 30, 2024) | |||
| Working Capital | $488,562 (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Volatility: Q3 2024 revenue dropped 99% year-over-year to $0.97 million compared to $84.9 million in Q3 2023. This decline is due to the recognition of significant collaboration revenue in the prior year related to BMS development services which were completed. Conversely, the nine-month revenue increased 46% to $133.0 million, driven by a $107.9 million recognition from the PRX019 Global License Agreement with BMS and $25.0 million from expired material rights.
- Profitability: The company reported a net loss of $59.0 million in Q3 2024, compared to a net income of $21.9 million in Q3 2023. The nine-month net loss improved to $64.4 million from $79.6 million in the prior year.
- Operating Expenses: Total operating expenses decreased 9% in Q3 2024 ($67.5M vs $74.6M) primarily due to lower manufacturing costs. However, for the nine-month period, expenses increased 9% ($222.7M vs $203.6M) driven by higher clinical trial costs for PRX012 and birtamimab.
- Liquidity: Cash and cash equivalents decreased by approximately $100 million during the nine-month period, primarily due to operating cash outflows of $102.3 million.
Guidance, Outlook, and Risks
- Clinical Milestones:
- Birtamimab: The Phase 3 AFFIRM-AL trial for AL amyloidosis is on track, with full topline results expected in the first half of 2025.
- PRX012: Phase 1 clinical readouts are expected starting mid-2025.
- PRX019: Phase 1 first-in-human trial initiated in November 2024.
- BMS-986446: BMS initiated a Phase 2 trial in early 2024.
- Liquidity Outlook: Management believes current cash of $519.3 million is sufficient to fund operations for at least the next 12 months. Additional capital will be required for future development and commercialization, potentially raised through equity, debt, or collaborations.
- Key Risks:
- Dependence on third-party collaborators (Roche, BMS, Novo Nordisk) for development and commercialization.
- Uncertainty regarding clinical trial outcomes and regulatory approvals.
- Need for additional financing; potential dilution to shareholders.
- Geopolitical risks affecting clinical trial sites (e.g., Israel, Eastern Europe).
Investor Verification Checklist
- Revenue Recognition: Verify the sustainability of revenue streams given the significant drop in Q3 2024 compared to Q3 2023, and the reliance on one-time license fee recognitions (PRX019) for YTD growth.
- Cash Burn Rate: Assess the $102.3 million cash used in operating activities over nine months against the $519.3 million cash balance to confirm the 12-month runway.
- Clinical Trial Progress: Monitor enrollment and data readout timelines for the Phase 3 AFFIRM-AL trial (birtamimab) and Phase 1 trials for PRX012 and PRX019.
- Collaboration Terms: Review the specific milestone triggers and payment structures in the BMS and Roche agreements to understand future revenue potential.
- Share-Based Compensation: Note the $35.4 million in share-based compensation expense for the nine months ended Sept 30, 2024, as a significant non-cash cost impacting net loss.